Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precigen Inc PGEN

Healthcare Biotechnology
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across... see more

Recent & Breaking News (NDAQ:PGEN)

Precigen Reports First Quarter 2024 Financial Results and Business Updates

PR Newswire 2 days ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

PR Newswire 8 days ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

PR Newswire April 24, 2024

Actym Therapeutics Appoints Thomas Smart as CEO

PR Newswire April 24, 2024

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

PR Newswire March 28, 2024

Precigen Reports Full Year 2023 Financial Results and Business Updates

PR Newswire March 19, 2024

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

PR Newswire March 12, 2024

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

PR Newswire March 5, 2024

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

PR Newswire February 6, 2024

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

PR Newswire January 16, 2024

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 8, 2024

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire December 18, 2023

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

PR Newswire November 29, 2023

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

PR Newswire November 9, 2023

Precigen to Participate in the Stifel 2023 Healthcare Conference

PR Newswire November 7, 2023

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

PR Newswire September 19, 2023

Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

PR Newswire August 14, 2023

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

PR Newswire August 9, 2023

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

PR Newswire August 9, 2023

Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th

PR Newswire August 3, 2023